Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Emami share buyback...

    Emami share buyback size likely to be Rs 900-1000 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 19 March 2020 3:30 AM  |  Updated On 19 March 2020 3:30 AM
    Emami share buyback size likely to be Rs 900-1000 crore

    Kolkata: The size of proposed buyback of shares by Emami Ltd is likely to be in the range of Rs 900-1,000 crore, sources said on Monday. The promoters currently hold 52.74 per cent stake in the company and 83 per cent of their holding is pledged.

    The buyback could raise promoter stake to about 58 per cent, sources said.

    The company's board will meet on March 19 to consider the buyback and an interim dividend.

    "The company's buyback will be within the window of 10 per cent of the reserves as this does not require any shareholder's nod," sources told.

    Based on the current level of share price, the size of the buyback could be between Rs 900-1000 crore, they said.

    As of March 2019, Emami had free reserves of over Rs 2,000 crore.

    In February, the promoters had entered into an agreement to sell their cement business to Nirma to pare debt at the promoter level and the sale process is expected to be completed by June.

    Meanwhile, an interim dividend will boost retail shareholders' morale amid volatility in the capital markets following the coronavirus scare, according to analysts.

    The latest Union budget had proposed that dividend distribution tax (DDT) will be levied on the recipients, which is set to adversely impact the high bracket taxpayers. The effective DDT rate was 20.56 per cent.

    Read also: Sun Pharma Nod To Rs 1,700 Crore Share Buy-Back Offer At Rs 425 Each

    buy-backemami
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok